ReviewThe oncologist2022
Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Review in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Seen on screen, missed in clinic: educational pearls fromSkin health and disease · 2026Review
- Acral Plantar Melanoma Mimicking a Diabetic Foot Ulcer in a Nonagenarian: A Case Report.Cureus · 2026Article
- Article
- Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities.Frontiers in oncology · 2026Review
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- Acral Melanoma in Ethnic Lebanese Arab Patients: 12-Year Experience with a Rare Disease in the MENA Region.Journal of clinical medicine · 2025Article
- Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Primary Sinonasal Mucosal Melanoma: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review.Cancers · 2025Review
- Primary malignant melanoma of the female urethra: A case report.Urology case reports · 2025Article
- Immunotherapy in Melanoma.Cancer treatment and research · 2025Review
- Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.Journal for immunotherapy of cancer · 2024Article
- Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma.The British journal of dermatology · 2024Article
- Survival of patients with mucosal melanoma in Cali, Colombia: a retrospective cohort study.BMC cancer · 2024Article
- The genetic evolution of acral melanoma.Nature communications · 2024Article
- Review
- Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy.Medical oncology (Northwood, London, England) · 2024Article
- Pressure and Skin: A Review of Disease Entities Driven or Influenced by Mechanical Pressure.American journal of clinical dermatology · 2024Review
- Melanoma biology and treatment: a review of novel regulated cell death-based approaches.Cancer cell international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acral and mucosal melanomas (MM) are rare subtypes of melanoma that are biologically and clinically distinct from cutaneous melanoma. Despite the progress in the treatment of cutaneous melanomas with the development of targeted and immune therapies, the therapeutic options for these less common subtypes remain limited. Difficulties in early diagnosis, the aggressive nature of the disease, and the frequently occult sites of origin have also contributed to the poor prognosis associated with acral and MM, with substantially worse long-term prognosis. The rarity of these subtypes has posed significant barriers to better understanding their biological features and investigating novel therapies. Consequently, establishing standardized treatment guidelines has been a challenge. In this review, we provide a brief overview of the current knowledge regarding acral and MM, focusing on their epidemiology, genetic backgrounds, and unique clinical characteristics. Further discussion centers around the management of primary and advanced disease and the role of emerging targeted and immune therapies for these subtypes, specifically focusing on issues relevant to medical oncologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.